Abstract
ABSTRACTTriple-Negative Breast Cancer (TNBC) is the most aggressive type of breast malignancy, with chemotherapy as the only mainstay treatment. TNBC patients have the worst prognoses as a large fraction of them do not achieve complete pathological response post-treatment and develop drug-resistant residual disease. Molecular mechanisms that trigger proliferation in drug-resistant chemo-residual TNBC cells are poorly understood due to the lack of investigations using clinically relevant cellular models. In this study, we have established TNBC subtype-specific cellular models of proliferating drug-tolerant persister (PDTP) cells using different classes of chemotherapeutic agents that recapitulate clinical residual disease with molecular heterogeneity. Analysis of total phospho-tyrosine signals in TNBC PDTPs showed an enhanced phospho-tyrosine content compared to the parental cells (PC). Interestingly, using mass-spectrometry analysis, we identified a dramatic decrease in epidermal growth factor receptor (EGFR) expression in the PDTPs, while the presence of hyper-activated tyrosine phosphorylation of EGFR compared to PC. Further, we show that EGFR has enhanced lysosomal trafficking in PDTPs with a concomitant increase in N-Myc Downstream Regulated-1 expression that co-localizes with EGFR to mediate receptor degradation. More surprisingly, we found that reduced protein levels of EGFR are coupled with a robust increase in Src family kinases, including Lyn and Fyn kinases, that creates a hyper-phosphorylation state of EGFR-Src tyrosine kinases axis in PDTPs and mediates downstream over-activation of STAT3, AKT and MAP kinases. Moreover, paclitaxel-derived PDTPs show increased sensitivity to EGFR TKI Gefitinib and its combination with paclitaxel selectively induced cell death in PDTP-P TNBC cells and 3D spheroids by strongly downregulating phosphorylation of EGFR-Src with concomitant downregulation of Lyn and Fyn tyrosine kinases. Collectively, this study identifies a unique hyper-phosphorylation cellular state of TNBC PDTPs established by switching of EGFR–Src family tyrosine kinases creating a vulnerability to EGFR TKI.
Publisher
Cold Spring Harbor Laboratory
Reference41 articles.
1. “Short-Term Single Treatment of Chemotherapy Results in the Enrichment of Ovarian Cancer Stem Cell-like Cells Leading to an Increased Tumor Burden;Molecular Cancer,2013
2. “Chemotherapy Confers a Conserved Secondary Tolerance to EGFR Inhibition via AXL-Mediated Signaling Bypass;Scientific Reports 2021 11:1,2021
3. “Targeting MTOR and DNA Repair Pathways in Residual Triple Negative Breast Cancer Post Neoadjuvant Chemotherapy;Scientific Reports 2021 11:1,2021
4. Bergin, Alice R.T. , and Sherene Loi . 2019. “Triple-Negative Breast Cancer: Recent Treatment Advances.” F1000Research 8. /pmc/articles/PMC6681627/ (May 18, 2022).
5. “Minimal Residual Disease in Cancer Therapy--Small Things Make All the Difference;Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,2015